Affiliation:
1. Lovely Professional University, India
Abstract
There has been a significant rise in the prices of medicines in the recent past. Major pharmaceutical companies, ‘Big Pharma', argue in favor of this development as it takes a lot of research and resources to bring a drug to market. Once in the market, the primary source of revenue generation for the companies is through sale of prescription drugs. Companies also have to spend a lot of their income on various marketing communication programs to convince their prescribers, even if it comes at costs that are difficult to ignore. This chapter studies the array of marketing strategies that are adopted by Big Pharma in developing and expanding their businesses. It also places these strategies within the context of the fast-growing generics market with its consequent changes to the marketing mix of the industry. While doing so, the chapter also explores and appreciates the various aspects of the pharmaceutical industry, as it presents features distinct from any other.
Reference46 articles.
1. Estimating The Cost Of New Drug Development: Is It Really $802 Million?
2. Annual Report 2022-23. (n.d.). Department of Pharmaceuticals, Ministry of Chemicals & fertilizers, Government of India. Available at: https://pharmaceuticals.gov.in/sites/default/files/Annual%20Report%202022-23%20Final-3_0.pdf
3. Association of Accessible Medicines. (2017). Generic Drug Access and Savings in the U.S. Available at https://accessiblemeds.org/sites/default/files/2017-07/2017-AAM-Access-Savings-Report-2017-web2.pdf
4. The refinement of the super generic concept: Semantic challenge for product re-innovation? Generics and Biosimilars Initiative (GaBI);F.Barei;Journal,2015
5. Switching from Originator Brand Medicines to Generic Equivalents in Selected Developing Countries: How Much Could Be Saved?